The French company Juvisé Pharmaceuticals has acquired the rights to develop and market the approved multiple sclerosis (MS)…
Articles by Patricia Inacio, PhD
The U.S. Food and Drug Administration has designated SetPoint Medical’s neurostimulator a breakthrough device for the treatment of…
Fatigue is a significant predictor of worse health-related quality of life in adults with relapsing-remitting multiple…
Tyruko (natalizumab), the first biosimilar of Tysabri, is now available in Germany for adults with highly active relapsing-remitting multiple sclerosis (RRMS).
Rocco Mangel, the founding partner of Rocco’s Tacos & Tequila Bar, is joining the Walk MS: West Palm Beach…
The U.S. Patent and Trademark Office (USPTO) has notified Vanda Pharmaceuticals that it will grant a new patent covering the…
Living with the human immunodeficiency virus (HIV) is linked to a significantly lower rate of developing multiple sclerosis (MS)…
Sudo Biosciences has raised $116 million in a Series B financing to support the clinical development of two inhibitors…
The rate of brain atrophy, or shrinkage, and changes in brain lesion volume in the first years of treatment with…
Tiziana Life Sciences has dosed the first patient in a Phase 2a clinical trial testing its foralumab nasal spray in…
The risk of falling among people with multiple sclerosis (MS) seems to be associated with a combination of personal,…
Vanda Pharmaceuticals has acquired the U.S. and Canadian rights to Ponvory (ponesimod), an oral therapy approved for relapsing types…
Adhering to an aerobic exercise program of moderate to intense cycling for 12 weeks significantly eased pain and fatigue in…
InSilicoTrials (IST) has received this year’s Innovation Radar Prize for its efforts to harness artificial intelligence (AI) to advance…
In children with pediatric-onset multiple sclerosis (POMS), poor sleep quality is linked to fatigue, depression, and worse quality of…
Losing the sense of smell is associated with a higher likelihood of worse disease outcomes for people with multiple…
Nabiximols, the cannabis-based oral spray sold as Sativex, is available for reimbursement as an add-on therapy for moderate to…
Vidofludimus calcium (IMU-838), an investigational oral therapy being developed by Immunic Therapeutics for all types of multiple sclerosis…
People with multiple sclerosis (MS) who switch between more than two disease-modifying therapies (DMTs) have a higher risk…
Assessing a person’s daily walking patterns using the Google Maps Timeline tool may help doctors remotely monitor fatigue, walking ability,…
FSD Pharma’s Lucid-21-302 — an oral treatment candidate known as Lucid-MS, for all types of multiple sclerosis (MS)…
Using disease-modifying therapies (DMTs) doesn’t reduce fatigue levels in people with multiple sclerosis (MS), a study in Norway…
Lapix Therapeutics is launching a Phase 1 clinical trial to evaluate LPX-TI641, its investigational treatment for autoimmune diseases such…
Swoop, a consumer health data company, is launching a first of its kind algorithm that’s designed to predict treatment…
People with multiple sclerosis (MS) are about two times more likely to have migraines than healthy people while migraines…
Bowel symptoms go largely unreported among people with multiple sclerosis (MS), mostly due to the unwillingness of patients to…
Ocrevus (ocrelizumab) will be funded in New Zealand for treating certain people with primary progressive multiple sclerosis (PPMS)…
Cionic’s Neural Sleeve, a leg-worn garment designed to boost strength and walking performance in people with conditions such as multiple…
A global Phase 2 clinical trial investigating the oral therapy vidofludimus calcium (IMU-838) in people with progressive forms of…
Disability progression in people with multiple sclerosis (MS) significantly reduces their quality of life, affects their ability to work,…